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Abstract 
α-syn is a cytosolic protein known for its association with neurodegenerative diseases that include 
Parkinson’s disease and other synucleinopathies. The potential cellular function of α-synuclein may be 
of consequence for understanding the pathogenesis of such diseases. Previous work has suggested that 
α-synuclein can catalyse the reduction of iron as a ferrireductase. We performed a detailed analysis of 
the steady-state kinetics of recombinant α-syn ferrireductase activity and for disease associated variants. 
Our study illustrates that the ferrireductase activity we observed is clearly commensurate with bone fide 
enzyme activity and suggest a mechanistic rationale for the activity and the relationship to cellular 
regulation of the pool of Fe(III)/ Fe(II). Using cell based studies we examined the functionally active 
conformation and found that the major catalytically active form is a putative membrane associated 
tetramer. Using an artificial membrane environment with recombinant protein, we demonstrate that 
secondary structure folding of α-synuclein is insufficient to allow enzyme activity and the absolute 
specificity of the tertiary/quaternary structure is the primary requirement. Finally, we explored the 
steady-state kinetics of a range of disease α-synuclein variants and found that variants involved in 
neurodegenerative disease exhibited major changes to their enzymatic activity. We discuss these data in 
the context of a potential disease associated mechanism for aberrant α-synuclein ferrireductase activity. 
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Introduction 
Alpha-synuclein (α-syn) is a member of a family of proteins termed the synucleins1, 2. It has been 
associated with a range of neurodegenerative diseases unified under the name of synucleinopathies, chief 
of which is Parkinson’s disease (PD) 3, 4. Other synuclein family members include β-synuclein (β-syn) 
and γ-synuclein. α-syn and β-syn are co-localised in neurons5, but α-syn has gained more attention, 
because of its potential to aggregate and form Lewy Bodies that are seen in the synucleinopathies 6. α-
syn is a 14 kD protein that has been most commonly described as a monomeric, unstructured protein of 
the cytosol. However, there is considerable evidence that it can associate with the plasma membrane and 
gain helical content 7-10. There is also evidence suggesting that some amount of the cellular form can 
form tetramers that are rich in helical content11. The function of α-syn in cells remains unclear. Knockout 
of the protein in transgenic mouse lines does not alter viability or brain architecture, but has mild effects 
on dopamine release 12. There are some reports that α-syn knockout alters behaviour13.  
 
Various molecular studies have suggested a range of functions for α-syn. As the protein is expressed in 
dopaminergic neurons, it has been suggested that the protein regulates dopamine release14. Particularly, 
α-syn is thought to be involved in SNARE dependent vesicle fusion leading to neurotransmitter release 
15.  This is supported by studies that suggest α-syn is localised to the presynaptic terminals16, but α-syn 
has also been found in the nucleus. In this case it has been suggested to have a role in gene transcription 
via inhibiting histone acetylation17. Other studies have suggested that α-syn is localised to the 
mitochondria, where it may be involved in mitochondrial function 18. α-syn has been suggested to bind 
metals including copper and iron. In this regard, α-syn has been suggested to catalyse the reduction of 
iron19. 
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Ferrireductase (FR) activity in cells is vital to ensure the availability of Fe(II) for a range of cellular 
processes and particularly those enzymatic activities that require Fe(II) as a co-factor. In dopaminergic 
neurons, such as those in the substantia nigra, lost during that pathogenic advance of PD, Fe(II) is 
required as a co-factor for tyrosine hydroxylase involved in the synthesis of dopamine20. PD is also 
associated with disturbances in brain iron homeostasis 21, 22. Recently, it has been suggested that α-syn 
can act as a ferrireductase19. Therefore, α-syn, which is highly expressed in the substantia nigra, could 
serve a role in the regulation of the balance of Fe(II) to Fe(III) in this key region.  
 
The previous evidence for the enzymatic activity of α-syn has come from studies with purified 
recombinant protein from bacterial sources and some studies of α-syn expressed in mammalian cells19. 
Overexpression of α-syn in cells elevated the level of Fe(II) present. While this evidence allowed us to 
demonstrate the FR activity, it did not provide evidence of the active species of the protein or which 
domains are necessary for its activity. Such information is of great interest given the recent identification 
of a tetrameric form of α-syn which has been suggested to be of great importance to understanding the 
protein’s normal role in cells. In this article we provide more complete evidence for the enzymatic role 
of α-syn in iron reduction and provide evidence that the active form is a membrane associate species that 
is either a dimer or a tetramer. 
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Materials and methods 
Reagents were purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated. 
 
Purification of synuclein proteins. Using pET expression vectors in BL21 E. coli cells, untagged α-syn 
protein expression was induced at OD600 0.5 – 1.0 with 1 mM IPTG for 4 hours. Cells were harvested by 
centrifugation (8000 x g) and lysed mechanically in 20 mM Tris-HCl/1 mM EDTA/pH 8.0 (Buffer A), 
1 mM PMSF and 50 µg/mL DNase. Streptomycin sulfate was added to a final concentration of 1% to the 
lysate solution then centrifuged at 8000 x g.  Ammonium sulfate (0.295 g/mL) was added to the 
supernatant (15% w/v solution) and stirred at 4 oC for at least 1 hour. After centrifugation at 10,000 x g, 
the pellet was resuspended 50 mL Buffer A. The semi-purified lysate solution was loaded onto a 10 mL 
Q Sepharose column (Amersham Biosciences). The column was washed with 100ml Buffer A, then 2 
column volume isocratic elution step to 25% Buffer A + 1 M NaCl (Buffer B). Synuclein proteins were 
eluted with a broad gradient elution (10 column volumes) from 25% Buffer B to 50% Buffer B (all 
synuclein proteins eluting at approximately 350 mM NaCl). SDS-PAGE analysis of Q Sepharose 
fractions was performed and fractions enriched for synuclein were pooled. Synuclein proteins were 
collected as flow through from a PM30 cellulose membrane (Millpore) then concentrated with a PM10 
PES membrane (Millipore). Purified synuclein proteins were dialysed extensively at 4 oC in chelex-
treated MilliQ. Protein Concentration was measured by absorbance at 275nm with extinction coefficient 
of 5600 M-1cm-1. Mutants of wild-type α-syn were as previously described23. Purity of the recombinant 
protein was confirmed through samples sent to the Mass Spectroscopy Facility at the University of 
Bristol. Examples of protein purification are included in the supplementary material (Suppl. 
 Figure 1) 
Cell culture. SH-SY5Y (human neuroblastoma) cells were cultured in 45% DMEM/45% Ham’s F12 
supplemented with 10% FBS, and 1% pen/strep.  Cells were maintained at 37oC and 5% CO2 in a 
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humidified incubator. The neuronal status of SH-SY5Y cells was monitored by RT-PCR with primers 
for tyrosine hydroxylase (TH), dopamine transporter (DAT) and vesicle mono-amine transporter 2 
(VMAT2). Cells were used within 20 passages of the original vial.  
 
Ferrireductase Assay. The ferrireductase activity was measured essentially as previously described 19, 
monitoring the concentration dependence of β-nicotinamide adenine dinucleotide hydride (NADH) and 
ferric ammonium citrate [Fe (III)]. For cell-based assays, cells were grown to 90% confluence and the 
flask of cells scraped into distilled water and centrifuged immediately at 13k r.p.m.  The resulting 
membrane pellets were then washed in PBS three times with subsequence centrifugation. The final pellet 
was the resuspended in PBS with 1% Igepal and incubated on ice for 20 minutes. The extract was then 
cleared of debris by centrifugation and the supernatant used for experiments. The protein concentration 
was determined using a standard Bradford Assay (Biorad) and applied to the ferrireductase assay. The 
cell-based assay used 20 mM MOPS pH 7, 500 µM NADH, 500 µM ferrozine and 250 µg/ml of the test 
protein. 
Stopped-flow fluorescence, circular dichroism and dynamic light scattering measurements. Absorbance 
changes were monitored on a thermostated Hi-Tech Scientific stopped-flow apparatus (TgK Scientific, 
Bradford on Avon, UK). Typically 3 - 5 transients were recorded for each reported measurement. 
Transients were fit as described in the text. Circular dichroism measurements were made on a 
thermostated Applied Photophysics Chirascan spectrophotometer (Applied Photophysics, Leatherhead, 
UK) using a high-quality quartz cell with a 0.1 mM path length. Dynamic light scattering (DLS) 
profiles were recorded using a Malvern Zetasizer DLS incubated at 25 °C recorded as percent volume. 
 
Nanodisc preparation. L-α-phosphatidylcholine from soybean (sigma P3644-25G) was resuspended in 
20 mM Hepes pH 7.5 100 mM NaCl to give a 10 mM suspension of liposomes. This suspension was 
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extruded for 15 passes through a 100 nm membrane (Sigma, WHA800309) using a mini extruder 
(Avanti Polar Lipids). Hydrolysed SMA polymer (3:1 ratio of styrene:maleic acid) was a gift from 
Professor Karen Edler (Dept. of Chemistry, University of Bath). The polymer was solubilised in 20 
mM Hepes pH 7.5 100 mM NaCl at 6% w/v. For preparation of nanodiscs a 1:3 ratio of 6% w/v SMA: 
10 mM extruded liposomes was incubated at 18oC for 2 hours. Nanodiscs preparations (1.5% w/v 
SMA, 7.5 mM lipid) were analysed by dynamic light scattering (DLS) for quality control. We note that 
the size of the nanodiscs as assessed by DLS corresponds with previous reports based on NMR studies 
(see below). 
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Results 
 
α-syn is a bone fide ferri-reductase. We used an established assay for detecting the formation of Fe(II), 
based on the optical absorption of 3-(2-pyridyl)-5,6- bis(phenyl sulfonic acid)-1,2,4-tri-azine 
(ferrozine) at 562 nm, which increases upon binding of Fe(II). The assay is highly specific for the 
presence of Fe(II) with essentially no change in the presence of Fe(III). This indirect assay has the 
potential to be a confounding factor in the analysis of ferri-reductase activity. That is, if the rate of 
Fe(II) binding to ferrozine is slow, or at least slower than the activity of the enzyme, then Fe(II) 
binding becomes the rate limiting step. We have therefore monitored the rate of Fe(II) binding to 
ferrozine, assessed by the absorption change at 562 nm in a stopped-flow apparatus. An example 
stopped-flow transient is shown in Figure 1A. The data fit to a single exponential function: 
ΔAobs = A exp(-kobst)                            Eq 1    
                                                                      
Where ΔAobs is the change in the observed absorption of ferrozine with respect to time (t), A is the 
amplitude of the kinetic transient giving an observed rate constant (kobs). 
That the data fit to a single exponential suggests only a single physical step in the binding interaction. 
The observed rate extracted from Eq 1 is kobs = 12.29 ± 0.1 s
-1. The observed rate of Fe(III) binding to 
ferrozine is therefore at least three orders of magnitude faster than the values of kcat we observe for α-
syn (vida infra) and so, at least for α-syn, the assay reflects enzyme turnover and Fe(II) formation. We 
cannot comment on the mechanistic step or steps we access with this assay however, other than it most 
likely reflects the slowest step in the turnover of Fe(III) to Fe(II). 
 
The key experimental test for enzyme activity is the observation of a linear relationship between the 
observed rate of turnover and the enzyme concentration. Figure 1B shows the concentration 
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dependence of α-syn on the observed rate of Fe(II) formation. We found that the data fit to a simple 
linear function that intersects both axes essentially at zero. That is, the rate of Fe(II) formation 
increases linearly with the concentration of α-syn, suggesting that the observed ferri-reductase reaction 
is truly enzyme catalysed by α-syn. As an additional step of verification we compared α-syn 
ferriductase activity with and without boiling of the protein. Boiling of the protein for 1 h completely 
inactivates the protein (Suppl. Figure 2). 
 
 
 
Figure 1. A, Characterisation of the assay used to detect ferrireductase activity. Stopped-flow kinetics 
monitoring the increase in absorbance at 562 nm upon rapid mixing of 10 μM Fe (II) with Ferrozine. 
The red line is the fit to a single exponential function. B, Steady-state kinetics monitoring the formation 
of Fe(II) in the presence of increasing concentration α-syn. The red dashed line is the fit to a linear 
function. C, Steady-state kinetics of α-syn monitoring the formation of Fe(II) as a function of increase 
NADH (red) and Fe(III) (black) concentration. Solid lines are fits to Eq 2 (red) and  Eq 3 (black). 
 
 
 
Figure 1C shows the concentration dependence of Fe(III) and NADH on the rate of Fe(II) formation in 
the presence of 100 μM α-syn. For NADH, we found that the data can be adequately fitted to the 
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Michaelis-Menten equation, giving values of kcat = 2.93 ± 0.95 (10
-2) min-1 and Km = 65.2 ± 26.9 mM. 
For Fe(III), the data do not fit to a simple Michaelis-Menten relationship (Eq 2) but instead show an 
initial increase on observed rate and then a decrease at higher Fe (III) concentrations. The data fit to a 
model that includes substrate inhibition (Eq 3), 
𝑣 =  
𝑘𝑐𝑎𝑡[𝐸]0[𝑆]
𝐾𝑚+[𝑆]
                                              Eq 2                                                                          
𝑣 =  
𝑘𝑐𝑎𝑡[𝐸]0[𝑆]
𝐾𝑚+[𝑆](
1+[𝑆]
𝐾𝑖
)
                                          Eq 3                               
 
Where Ki is an inhibition constant. Fitting the data to Eq 3 gives, kcat = 3.66 ± 4.9 (10
-2) min-1, Km = 7.0 
± 10.5 mM and Ki = 0.57 ± 0.85. The magnitude of kcat is relatively small. This could point to either a 
high barrier to transition-state formation, a very slow rate-limiting step in the overall enzymatic 
turnover (including substrate binding, chemical turnover and product release) or a small fraction of the 
total protein being in a catalytically competent conformation. The observation of a large Km value in 
the mM region for both NADH and Fe (III) suggests the ternary reactive complex is weakly bound. 
 
For such a two-substrate system, one would like to make the steady-state measurements at a saturating 
concentration of one substrate. This is not possible in the present case since the 𝐾M
app
 values are large 
and to saturate these would place the concetrations beyond the solubility limits of the substrates. We 
therefore prefer to interpret the relative trends in our data rather than the absolute magnitudes. 
 
α-syn variants suggest a pathological link to ferri-reductase activity. We explored the Stead-state 
kinetics of a range of key, pathologically relevant α-syn variants shown in Figure 2A and 2B with the 
resulting extracted values from the fits given in Table 1. Figure 2C shows a summary of our findings 
with respect to the structural location of the α-syn variants. 
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Figure 2. Steady-state kinetics of α-syn showing concentration dependencies with NADH (Panel A) 
and Fe3+ (Panel B). Solid lines are fits to models described in Table 1, with the corresponding extracted 
parameters. Wild-type synuclein (black), H50Q (coral), A53T (blue), E46K (yellow), Δ119-126 
(green), Δ2-9/H50A (lilac). C, Summary of the effect of different variants on the steady-state kinetics 
of α-syn. 
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Table 1. Extracted parameters from steady-state data fitting shown in Figure 2. 
 𝑉max
app
 (μM/min) 𝐾M
app
 
(mM) 
𝑘cat
app
 (min-1) 𝑘cat
app
/𝐾M
app
 
(min-1 mM-1) 
𝐾i
app
 
(mM) 
n 
[NADH] - dependence 
α-syna  2.93 ± 0.95 65.2 ± 
26.9 
2.93  10-2 4.50  10-4 - - 
Δ119-126 2.5 ± 0.7 80.9 ± 
32.8 
2.5  10-2 3.1  10-4 - - 
H50Qb 0.12 ± 0.02 5.0 ± 0.8 0.12  10-2 2.4  10-4 63.3 ± 
40.0 
2.1 ± 0.3 
A53T 0.94 ± 0.24 45.6 ± 
17.5 
0.94  10-2 2.0  10-4 - - 
E46K 0.19 ± 0.03 32.9 ± 
10.4 
0.19  10-2 5.7  10-5 - - 
Δ2-9/H50A 0.20 ± 0.15 73.6 ± 
82.5 
0.20  10-2 2.7  10-5 - - 
[Fe3+] - dependence 
α-sync 3.66 ± 4.9 7.0 ± 10.5 3.66  10-2 5.2  10-3 0.57 ± 
0.85 
- 
Δ119-126 0.55 ± 0.02 0.46 ± 0.1 0.55 10-2 1.12  10-2 5.43 ± 
0.53 
- 
H50Qb 0.13 ± 0.06 2.3 ± 0.4 0.13  10-2 6  10-6 7.1 ± 5.8 5.4 ± 3.0 
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A53T 0.84 ± 0.24 3.14 ± 1.6 0.84  10-2 2.7  10-5 13.8 ± 7.5 - 
E46K 0.21 ± 0.03 1.9 ± 0.57 0.21  10-2 1.1 10-6 10.0 ± 3.1 - 
Δ2-9/H50A 0.25 ± 0.1 3.39 ± 1.8 0.25  10-2 7.2 10-6 5.0 ± 2.8 - 
a, MM kinetics. b, Substrate inhibition. c, Cooperative binding and substrate inhibition. In all cases the 
simplest model was selected based on the extraction of realistic fitting parameters and statistical quality 
of the fit. 
 
 (i) A53T and E46K are mutations in the SPCA gene associated with inherited forms of PD. The Km 
was relatively unaffected for NADH with a decrease for Fe3+ but kcat was significantly reduced in both 
cases. (ii) H50Q is a mutation identified from inherited cases of PD.  The H50 site could influence 
metal binding and is associated with increased oligomerisation and fibril formation of α-syn. We find a 
significantly reduced Km but also a significantly lower kcat for both NADH and Fe(III). We observed a 
complex kinetic relationship for both substrates, exhibiting both a sigmoidal relationship, suggestive of 
cooperatvity, as well as substrate inhibition. We fitted these data to the function: 
𝑣 =  
𝑘𝑐𝑎𝑡[𝐸]0[𝑆]
𝑛
𝐾𝑚
𝑛 +[𝑆]𝑛+(
1+[𝑆]𝑛
𝐾𝑖
)
                                     Eq 4                                                           
Such a relationship is paradigmatic of the activity of other enzymes for example aspartate 
transcarbamylase24. These data therefore suggest either induction or unmasking of a cooperative 
relationship. Potentially these data may indicate that there are multiple discrete binding geometries for 
both NADH and Fe(III) in the H50Q variant and certainly that this metal binding site is key to the 
forming the optimal reactive geometry with both substrates. (iii) Δ2-9/H50A is a deletion of the N-
terminus of the protein that has been shown to be the site of high affinity copper25 binding and also 
removes the H50 residue from any potential role in metal binding.  The Km is relatively unaffected for 
NADH with a decrease for Fe(III) but kcat is significantly reduced in both cases. These data therefore 
suggest that the N-terminus is not significantly involved in the binding of either NADH or Fe3+, but is 
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required for full enzymatic activity. Potentially the copper binding increases the propensity to form a 
catalytically competent conformation. (iv) Δ119-126 represents the removal of a potential low affinity 
divalent metal binding site. The kcat and Km for NADH are hardly affected by this variant but both the 
kcat and the Km are significantly affected for Fe(III). The mutant data suggest this site is not involved in 
NADH binding or oxidation but is key to reduction and binding of the Fe(III). 
 
Differences in kcat between the mutants could be explained either by different conformational states of 
the proteins or by a smaller/larger proportion of a catalytically active conformation or alternatively as a 
consequence specifics of the two-substrate mechanism. However, differences in the equilibrium 
constants Km and Ki are not dependent on the proportion of the catalytically active species, but instead 
on differences in binding geometry, particularly for the reactive complex. That we observe significant 
changes in kcat, Km, Ki and the induction of cooperative like behavior (H50Q) argues strongly for 
structurally different forms of the mutants studied. Crucially this does not rule out a fraction of the 
recombinant protein being active and we explore this possibility below. We note that we do not suggest 
that the observed kinetic differences are the sole driver of disease state, since clearly aggregation 
propensity is a key factor. However, the key finding is that these data demonstrate that these disease 
variants can significantly alter the kinetics of FR activity. 
200 220 240
-2x10
6
-1x10
6
0
1x10
6

 M
o
la
r 
(d
e
g
 c
m
2
 d
m
o
l-1
) 
 (nm)
 wt
 H50A
 A30P
 2-9
 119-126
 A53T
 
15 
 
 
Figure 3. Far-UV CD spectra of recombinant α-syn and variants.  Solid lines are spectra corresponding 
to each variant and the dashed lines are the corresponding difference spectra for each variant with 
respect to WT α-syn. 
 
CD Analysis We have explored whether there is evidence of α-syn mutant conformational change through 
comparative far-UV circular dichroism (CD) spectroscopy shown in Figure 3. The Far-UV CD spectra 
of each mutant, as with WT α-syn, are indicative of a protein with an extremely high degree of 
unstructured content. However, the spectra show clear differences; the dashed line in Figure 3 shows the 
difference spectra of each mutant compared to the WT α-syn. In the case of A30P, A53T and Δ119-126 
α-syn the difference spectra are extremely characteristic of unstructured content with a negative peak at 
~198 nm and a small broad and positive peak at ~220 nm. The difference spectra for H50A and Δ2-9 are 
complex and do not present an obvious structural interpretation. Far-UV CD data are limited in the ability 
to quantitatively interpret unstructured content. However, our data suggest there is at least some 
conformational difference arising from the mutations studied. These data therefore provide a rationale 
for the different equilibrium constants, suggesting that the mutant structures affect the formation of the 
reactive ternary complex and potentially part of the differences in the extracted kcat values. The absolute 
magnitude of the kcat value for the mutants studied might vary based on an increasing/decreasing 
concentration of a specific structural form. Particularly given the unordered structure of WT and mutant 
proteins, there is significant scope for a broad equilibrium of conformational states and we explore this 
possibility below.  
 
Identification of the active structural form. We have previously shown FR activity of α-syn in cells 19. 
The cell based system has a distinct advantage over pure recombinant protein in that it is possible to 
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assess the localization of an active form of the protein.  Ferrireductases are frequently membrane 
associated 26 27. α-syn is also known to have a membrane association 28. Therefore, we investigated the 
possibility that α-syn present in the membrane is more FR active than that present in the cytosol. A crude 
membrane extract was made from SH-SY5Y cells overexpressing α-syn. The level of α-syn present was 
compared between membrane and cytosolic fraction using western blot (Figure 4a). The majority of 
detectable protein was present in the cytosol. However, a small percentage was membrane associated. 
The quality of membrane isolation was verified using western blotting of the Na/K ATPase antiporter. 
The level of FR activity was then assessed for the membrane and cytosolic fractions and compared to 
activity in an unfractionated cell extract (total). Virtually all of the FR activity was present in the 
membrane rich fraction despite containing only a small fraction of the total cellular α-syn (Figure 4b). 
The implication is that the majority of FR activity present in α-syn overexpressing cells is located in the 
membrane fraction of SH-SY5Y cells. As a further step to verify that this activity was from α-syn we 
used a specific monoclonal antibody to immunoprecipitate (IP) α-syn from the membrane fractions. 
Ferriredactase activity was only associated with anti- α-syn IP material but not IP material when a control 
antibody was used (Suppl. Figure 3). 
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Figure 4. Identifying the structural form of FR active α-syn. A, Western blot of equivalent volumes of 
protein extracts prepared from SH-SY5Y cells overexpressing α-syn, separated into cytosolic and 
membrane fractions. The levels of α-syn and Na/K ATPase assessed by immunodetection. B The 
fractions from Panel A were then assayed for FR activity, quantified based on differences in the 
observed initial rate of ferrozine absorption change in the presence of 500 μM Fe(III). C, Western blot 
detecting cross linked α-syn from the SH-SY5Y fractions from Panel A. D, The relative amount of 
different α-syn oligomers from panel C were detected by densitometry. Data are the mean and s.e.m. 
for four experiments.  
 
The localization of a small fraction of α-syn to the cell membrane and the association of this fraction 
with the majority of FR activity infers the structural identity of the most active species of α-syn. There 
has been suggestion that α-syn can be expressed in cells as a helical tetramer 11. Identification of 
tetrameric α-syn can be achieved by cross-linking of the protein within cell extracts. Total, membrane 
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and cytosolic fractions of SH-SY5Y cell overexpressing α-syn were cross-linked and α-syn identified 
using western blot (Figure 4c). After fractionation, virtually all dimeric and tetrameric species of α-syn 
were present in the membrane fraction with almost solely monomeric protein in the cytosolic fraction. 
Also, in comparison to the total fraction, the level of tetrameric protein is clearly enriched. This strongly 
supports the notion that the active species is the tetrameric form of α-syn. Potentially the relatively small 
activity of the cytosolic fraction is attributable to the present of a minor amount of enzymatically active 
oligomeric α-syn present in the cytosol (Figure 4d). 
 
Figure 5. Steady-state kinetics of protein extract from α-syn expressing cell lines showing 
concentration dependencies for Fe(III). The membrane fractions from the cells were prepared as in 
Panel A. Protein concentrations were 250 μg/ml. The extracted kinetic parameters are given in Table 2. 
 
Our finding that the major species showing ferriductase activity is associated with the membrane affords 
the opportunity to explore FR activity in the structural form found in the membrane, which we infer is a 
helical tetramer as described by others11, 29. To that end we have prepared protein extracts of the 
membrane fraction from cell lines overexpressing α-syn and a range of mutants. We assessed the kinetics 
of Δ2-9, Δ1-100, H50A, Δ2-9/H50A and Δ2-9/H50A/Δ111-140 to explore whether selected mutants 
have an additive effect. The observed activity with respect to Fe (III) concentration is shown in Figure 5 
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at essentially the same concentration of extracted total protein (250 µg/ml) and the extracted kinetic 
parameters in Table 2. The concentration range of Fe(III) we explore is necessarily more restricted 
compared to our recombinant protein studies because of the inherent capacity of high iron concentrations 
to cause cell components to precipitate. We therefore focus on the general trends that are apparent from 
the fitting shown in Figure 5. From the extracted kinetic parameters it is apparent that the variant enzymes 
show significant differences in the overall rate of turnover (asses by Vmax, not kcat since we do not know 
the precise enzyme concentration). Perhaps most importantly and consistent with our recombinant 
protein studies above, there is a clear difference in Km, suggesting structurally different forms of the 
reactive complex geometry between the mutants. Notably, the triple mutant, Δ2-9/H50A/Δ111-140, has 
the lowest activity approaching that of the empty vector control cell extract (Table 2). Whilst we have fit 
the control vector to the Michaelis-Menten equation this is more for comparison since we do not expect 
these data to obey saturation behavior with respect to Fe (III) concentration and the fitting simply serves 
to illustrate the extremely small signal arising from potentially other membrane associated 
ferrireductases. 
 
Table 2 . Extracted parameters from steady-state data fitting shown in Figure 5. 
 Vmax (μM/min) Km (mM) 
α-syn 0.066 ± 0.02 1.28 ± 0.59 
H50A 0.034 ± 0.003 0.46 ± 0.08 
Δ2-9 0.018 ± 0.002 1.53 ± 0.19 
Δ2-9, H50A 0.056 ± 0.014 1.68 ± 0.6 
Δ1-100 0.026 ± 0.003 0.40 ± 0.1 
Δ2-9, Δ111-140, H50A 0.01 ± 0.002 0.5 ± 0.2 
pCDNA (negative control) 0.005 ± 0.001 255.9 ±  51 
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We wished to explore whether an artificial membrane environment could be used to drive the formation 
of helical α-syn and whether this is sufficient to induce FR activity. Recent studies have demonstrated 
that nano-discs – defined artificial membrane environments – can be used to induce α-syn to form helical 
multimers30. As these nano-discs had a protein scaffold they are not compatible with many protein 
biophysical techniques due to background ‘noise’ from the discs themselves. For this reason we used 
styrene-malate polymer scaffolds to make nanodiscs. These have been shown to be compatible with a 
range of optical biophysical measurements including CD and dynamic light scattering (DLS). We have 
incubated 5 μM recombinant α-syn in the presence of 50 μM lipid nanodiscs diluted from 7.5 mM 
nanodiscs prepared as described in materials and methods31. To assess α-syn incorporation and folding 
into the nanodiscs, we have monitored the far-UV CD spectra and the dynamic lights scattering (DLS) 
profile as shown in Figure 6A and 6B, respectively. We find that when α-syn is incubated with the 
nanodiscs, the far UV-CD data become consistent with a protein that is predominantly helical, showing 
negative ellipticity centered at ~205 and 222 nm. From Figure 6B, the DLS data show that the 
recombinant α-syn is initially at a high hydrodynamic diameter, indicative of a low n aggregated species. 
From Figure 6B the nanodiscs give a diameter ~ 10nm, consistent with previous reports of nanodiscs of 
this composition32. Incubation with the nanodiscs disaggregates this species, suggesting that the helical 
species incorporated into the nano-discs is not an aggregate or large multimer. On assaying the nanodisc 
- α-syn species with the FR assay described above, we found no detectable FR activity.  
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Figure 6. α-syn incorporation into nanodiscs. A, Far-UV CD spectra of recombinant free α-syn and 
bound to nanodiscs. B, DLS (volume) profiles of recombinant free α-syn and bound to nanodiscs.  
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Discussion 
 
The function of many proteins associated with neurodegenerative diseases remains unresolved and 
frequently controversial. This is especially true for α-syn, a protein heavily implicated in a range of 
diseases collectively termed the synucleinopathies. The interest in the identification of a function for 
these proteins underlies the possibility that a loss or alteration of this function may play a causal role in 
the pathology. α-syn has been linked to altered metal metabolism. In PD there is especially a well-known 
change in iron metabolism21, 22, 33. Therefore, a function for α-syn related to iron is of great significance.  
 
We previously provided evidence that α-syn acts as an FR19. An FR plays a vital role in a cell that requires 
Fe(II) as it allows the regeneration of this form of iron which is vital for many cellular activities. In 
dopaminergic neurons Fe(II) is required as a cofactor for tyrosine hydroxylase the key, rate limiting 
enzyme in the synthesis of dopamine. We showed that α-syn can increase cellular Fe(II) levels and that 
cells with increased α-syn have increased FR activity. Additionally, we showed using recombinant 
protein that α-syn exhibits FR activity when purified. In this report we provide a much expanded 
concentration range of substrates and explore the concentration-dependence of both NADH and Fe(III). 
These data allow greater insight in to the FR activity of α-syn, providing evidence of its bona fide 
enzymatic status, the role of substrate inhibition, and its dependence on NADH for activity. Most 
significantly we have provided evidence from cell studies that the active form of α-syn is a tetramer. This 
supports recent studies that have pointed out the structured (helical) tetrameric species as the more 
important subspecies in vivo11, 34, 35. 
 
Potentially, the α-syn ferrireductase activity is relatively low because only a small fraction of the 
protein exists in a conformation that is catalytically competent. This is highly likely as demonstrated by 
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the cell extract data where activity is associated with a subspecies isolated from membrane. It is 
important to note that when considering the recombinant protein that the amount of tetramer present is 
much less that the amount that can be detected in cells (around 2% of the total, data not shown). 
Alternatively, the activity could be relatively low because α-syn is primarily disordered in solution and 
so lacks a well-defined reactive geometry in the active site. This is less likely if the active species is a 
tetramer, as this has been shown to have high helical content 11, 35. However, we note that the 
magnitude of Km is independent of enzyme concentration and so even if a small fraction of the protein 
is catalytically active, the enzyme itself still displays a high Km in relation to the cellular concentrations 
of both NADH and Fe3+. Clearly however, local concentrations of substrates can be very much higher 
at the microscopic level.  
 
From our recombinant protein studies we have found that the data fit to a model that includes substrate 
inhibition. The observation of substrate or product inhibition is relatively common and usually implies 
that the active site geometry can accommodate the substrate in more than one unique conformation, and 
at least some of these conformations are not catalytically competent. Typically, one observes the Ki value 
to be rather larger than the Km since the binding of the substrate in the catalytically competent 
configuration is anticipated to be higher affinity than non-competent configurations. However, we find 
that for Fe (III) there is a ‘turned-out’ relationship for Km and Ki, with the Ki being rather smaller than 
the Km. A consequence of this unusual relationship is that wild-type α-syn exhibits a very sharp 
concentration dependence in activity as shown in Figure 2. We suggest that the relationship between Km 
and Ki could be functionally important in governing the dose-response relationship of the intracellular 
pool of Fe(III)/ Fe(II). That is, the ferrireductase activity of α-syn will only become significant over a 
very narrow concentration range of available Fe(III). 
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Our data suggest that the enzymatically active form of α-syn is a membrane associated species, most 
likely to be the helical tetrameric species described recently11. However, we find that α-syn helicity is 
not itself sufficient to induce FR activity, with our artificial nanodisc - α-syn preparations showing no 
FR activity. Instead the FR activity is primarily associated with a structural form found in non-artificial 
cell membranes. These data argue that it is the precise quaternary structure of α-syn oligomers that define 
an active site compatible with FR activity. This finding suggests a possible mechanism by which α-syn 
acts as a ferrireductase. FR activity very commonly proceeds through a flavin intermediate, with hydride 
transfer from NAD(P)H, reducing the flavin and with subsequent reduction of Fe (III)36. Four-helix 
bundle architectures have been shown to bind flavin moieties and act as flavoenzymes37 A realistic 
possibility for the FR activity of α-syn is therefore that the helical tetrameric assembly is capable of 
(likely weakly) binding flavin and using this species as a coenzyme to catalyse the reduction of Fe (III). 
This notion is satisfying since it would explain why we find the large majority of the FR activity 
associated with the membrane fraction where one expects the native helical tetramer to be prevalent. 
Moreover, this hypothesis would be consistent with the need of the helical oligomeric assembly to adopt 
a precise quaternary arrangement.  
 
Kinetic assays with purified membrane protein fractions show saturation kinetics and the mutant proteins 
we have monitored show significant differences in both the overall turnover rate and the Km. These data 
therefore are consistent with our recombinant protein assays in demonstrating that α-syn variants can 
affect the FR activity. The observed differences in overall turnover and Km might point to difference in 
the active site architecture. That said we have shown previously that the Δ2-9/H50A mutant and deletions 
of the C-terminus alter membrane association 38. The difference in the observed activity might therefore 
have an origin in an altered concentration of a catalytically competent structural form, i.e. membrane 
associated versus soluble. Another possibility is that the mutations alter the rate of tetramer formation. 
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A recent paper has identified the KTKEGF repeat regions through the protein sequence as being essential 
for tetramer formation. In contrast deletions of 10 amino acid residue stretches (eg. Δ2-10) had no effect 
on tetramer formation 34. The implication is that changes in activity seen in our mutants are unlikely to 
be due to altered tetramer formation but instead are likely due to changes in membrane association. 
However, the key finding is these data support our notion that the FR active species is membrane 
associated and by inference the recently identified helical tetramer structural form. 
 
The FR activity of α-syn is potentially important in understanding its pathological role, particularly since 
iron homeostasis is known to be important in PD. Herein we sought to explore steady-state kinetics of α-
syn FR activity with a range of disease associated variants and exploring the nature of the catalytically 
active species. By exploring extended concentration ranges for the two substrates [NADH and Fe(III)] 
we found that turnover with NADH follows classical Michaelis-Menten kinetics, but with Fe(III) there 
is very significant substrate inhibition. Most importantly the kinetics of enzyme turnover, notably the 
inhibition and Michaelis constants, were significantly different with the disease variants. These data 
suggest that known disease variants of α-syn can ‘tune’ the FR activity. The observed rate of enzyme 
turnover are slow and we suggest this is because only a fraction of the enzyme is in a catalytically 
competent conformation, lacks a necessary cofactor or both. Whole cell assays point to the FR active α-
syn being a membrane associated tetrameric species, which we suggest is the recently identified helical 
tetrameric form. By using artificial membrane constructs (nanodiscs) we found that inducing α-syn to 
form a helical conformation is not itself sufficient to induce FR activity, suggesting that the absolute 
precision of the quaternary arrangement of helical α-syn monomers is necessary to define the 
catalytically active species. We go on to suggest that a rational mechanism for the FR activity of α-syn 
might be the binding of a flavin coenzyme by the helical tetrameric α-syn, which then mediates the 
electron transfer from NADH to Fe(III) as in other ferrireductases. 
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